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2060Objective: Bicuspid aortic valve (BAV) disease is associated with aortic dilatation and aneurysm (AN) forma-
tion. The American College of Cardiology/American Heart Association (ACC/AHA) 2006 guidelines recom-
mend replacement of the ascending aorta for an aortic diameter (AD)>45 mm in patients undergoing aortic
valve replacement (AVR). We evaluated the outcomes of AVR and AVR with aortic replacement (AVR/AN).
Methods: We retrospectively reviewed (2004-2011) the data from 456 patients with BAV and compared the
morbidity and mortality between the AVR and AVR/AN groups and 3 subgroups: AVR with an AD< 45
mm; AVR/AN with an AD of 45 to 49 mm; and AVR/AN with an AD of 50 mm. Propensity score matching
was used to reduce bias.
Results: Of the 456 patients, 250 (55%) underwent AVR and 206 (45%) AVR/AN, with 98% compliance with
the current guidelines. The overall 30-day mortality was 0.9%. The AVR AD< 45-mm group had adjusted
short- and medium-term survival similar to that of the AVR/AN AD 45- to 49-mm and AVR/AN AD
 50-mm groups, with a 30-day mortality of 0.8%, 0%, and 1.9%, respectively (P ¼ .41). The propensity
score-matched AVR/AN AD  50-mm group had significantly greater rates of reintubation than either the
AVR AD<45-mm (P ¼ .012) or AVR/AN AD 45- to 49-mm (P ¼ .04) group and greater rates of prolonged
ventilation (P ¼ .022) than the AVR AD<45-mm group. No significant differences were found in reoperation
or myocardial infarction among the subgroups.
Conclusions: In patients with undergoing AVR, no increase was seen in morbidity or mortality when adding
aortic replacement with an AD of 45 to 49 mm, in accordance with the 2006 ACC/AHA guidelines, although
the AVR/AN AD  50-mm group had a greater risk of respiratory complications. Our findings indicate that
compliancewith the ACC/AHA guidelines is safe in select centers. (J Thorac Cardiovasc Surg 2014;148:2060-9)See related commentary on pages 2070-1.Bicuspid aortic valve (BAV) disease is the most common
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The Journal of Thoracic and Cardiovascular Surpopulation.1,2 Although the exact mechanism is not yet
fully understood, BAV is a significant risk factor for aortic
dilatation, aneurysm (AN) development, and acute
dissection.2 Recent evidence has indicated dilatation of the
ascending aorta occurs secondary to degeneration of the
aortic media, similar to other connective tissue disorders, pri-
marily owing to apoptosis of neural crest derivatives.2
Regardless of the causative mechanism, the lifetime risk of
aortic dissection in patients with BAV has been reported to
be approximately 5 to 9 times greater than that of the general
population.2-5 The guidelines for themanagement of valvular
heart disease issued by the American College of Cardiology
and American Heart Association (ACC/AHA) task force in
2006 have recommended replacement of the ascending
aorta in patients with BAV in whom the aortic diameter
(AD) is>50 mm.6 Additionally, for patients with BAV who
meet the criteria for aortic valve replacement (AVR), the
guidelines have recommended replacement of the ascending
aorta at valve replacement (AVR/AN) for aortic dilatation
>45 mm.6 These specific recommendations, based on expert
consensus and retrospective observational series, were a new
addition to the 2006ACC/AHAguidelines comparedwith the
1998 version for valvular heart disease and have not been
formally evaluated in a large contemporary series of patients.7gery c November 2014
Abbreviations and Acronyms
ACC ¼ American College of Cardiology
AD ¼ aortic diameter
AHA ¼ American Heart Association
AN ¼ aneurysm
AVR ¼ aortic valve replacement
BAV ¼ bicuspid aortic valve
CAD ¼ coronary artery disease
CI ¼ confidence interval
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MRI ¼ magnetic resonance imaging
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compliance with the 2006 ACC/AHA guidelines in patients
with BAV undergoing AVR and to determine whether the
addition of aortic replacement in patients with an AD of
45 to 49 mm would be associated with increased perioper-
ative and medium-term morbidity and mortality.
METHODS
Patient Population
Data for the present project were obtained from the Cardiovascular
Research Database in the Clinical Trial Unit of the Bluhm Cardiovascular
Institute at Northwestern Memorial Hospital. The institutional review
board at Northwestern University approved the use of this database (proj-
ect no. STU00012288). Any subjects refusing participation in the project
were not included in the analysis. The Cardiovascular Research Database
was queried for patients with BAV who had undergone aortic valve sur-
gery from April 2004 to March 2011, and a total of 470 patients was
found. After excluding patients with preoperative aortic dissection
(n ¼ 4), ventricular assist device or transcatheter aortic valve implanta-
tion (n ¼ 5), and missing aortic measurements (n ¼ 5), we arrived at a
final cohort of 456 patients. Preoperative computed tomography (CT)
or magnetic resonance imaging (MRI) was performed in 417 patients
(91.4%) to assess aortic dilatation, which was the current practice in
our center for patients with a suspicion of BAV before surgery. Echocar-
diographic data were used when CT or MRI information was not avail-
able. Coronary artery disease (CAD) information was available for 447
patients. Of them, 115 (26%) had CAD. For 9 patients (age, 33.6 
8.9 years; 3 emergency cases) no CAD data were available. Pulmonary
hypertension (pulmonary artery systolic pressure>35 mm Hg) was pre-
sent in 108 (30%) of the 363 patients with information available. Aortic
stenosis and aortic insufficiency 2þ was present in 70% and 48%,
respectively (Table 1).
Outcome Measurements
The short-term outcomes included length of intensive care unit stay,
perioperative complications, and operative, in-hospital, and 30-day mortal-
ity according to The Society of Thoracic Surgeons database definitions.
Survival after discharge was determined from the Social Security Death In-
dex and chart review, in addition to annual mailed questionnaires and tele-
phone surveys obtained as part of a routine protocol for the Cardiovascular
Research Database registry. To evaluate the effect of the AD cutoff points
suggested by the 2006 ACC/AHA guidelines, we identified 3 subgroups of
interest: (1) AVR with an AD<45 mm, (2) AVR/AN with an AD of 45 toThe Journal of Thoracic and Car49 mm, and (3) AVR/ANwith an AD of50 mm. Pairwise comparisons of
these 3 subgroups were performed as follows:
1. AVR AD<45 mm compared with AVR/AN AD of 45 to 49 mm: these
cohorts were closest to the ACC/AHA recommended cutoff values and,
hence, were likely to provide the most practical validation of the guide-
lines. If worse outcomes occurred with the addition of ascending aortic
replacement surgery, it would be most likely to be observed in this AVR/
AN cohort
2. AVR AD<45 mm compared with AVR/AN AD of 50 mm
3. AVR/AN AD of 45 to 49 mm compared with AVR/AN AD of 50 mmStatistical Analysis
To reduce potential confounding owing to baseline imbalances, propen-
sity score (PS)matchingmethods were used.8 The patient groups compared
were PS-matched 1-to-1 using a greedy algorithm with a caliper size of
0.05 logit PS standard deviation units. Balance in the baseline characteris-
tics in the PS-matched groups was assessed using formal statistical testing
and confirmed by way of kernel-smoothed PS histogram similarity
(Figure 1). The matching factors included age, gender, body surface
area, preoperative creatinine level, preoperative left ventricular ejection
fraction, Ambler score, angina, CAD, family history of CAD, diabetes,
hypercholesterolemia, hypertension, cerebrovascular accident, previous
coronary artery bypass grafting, previous valve surgery, previous heart fail-
ure, New York Heart Association functional class III-IV, history of atrial
fibrillation, preoperative medication (eg, b-blockers, angiotensin-
converting enzyme inhibitors, lipid-lowering, calcium channel antago-
nists), aortic insufficiency 2, aortic stenosis, elective status, and surgeon.
Postoperative overall survival was summarized using Kaplan-Meier
curves, and group comparisons were based on the log-rank test. Medium-
term mortality comparisons in PS-matched groups also included age-,
gender-, and surgeon-adjusted PS pair-stratified Cox regression model
with robust covariance matrix.9 Hazard ratios (HRs) and corresponding
95% confidence intervals (CIs) were determined. The appropriateness of
the proportional hazards assumptionwas assessed visually. The baseline de-
mographics and preoperative characteristics are summarized in Table 1, and
the operative details and outcomes are listed in Table 2. The outcomes be-
tween the subgroups of interest using PS matching are listed in Table 3.
One-way analysis of variance or Kruskal-Wallis test was used to compare
the continuously distributed variables. The chi-square test or Fisher’s exact
test was used to compare the discrete variables. Medium-term survivorship
in the PS-matched analyses is displayed in Figure 2. Throughout, a 2-sided
5% statistical significance level was used, without multiplicity adjust-
ments. All statistical analyses were performed using Statistical Analysis
Systems, version 9.3, software (SAS Institute, Inc, Cary, NC).RESULTS
In the entire cohort of 456 patients with BAV, the overall
30-day mortality (Table 2) was 0.9% (n¼ 4). Perioperative
events included 3 strokes (0.7%), 1 perioperative myocar-
dial infarction (0.2%), and 30 reoperations for bleeding
(6.6%; Table 2). The average patient follow-up was 4.7 
2.1 years, and the incidence of perioperative or later aortic
dissection was 0%. Of the 456 patients with BAV, 250
(55%) were in the AVR group and 206 (45%) in the
AVR/AN group, for a 98% compliance rate with the 2006
ACC/AHA recommendations for aortic replacement in
those with an AD of 45 mm. No significant differences
were found in the short- or medium-term outcomes between
the AVR and AVR/AN groups regarding any complications
(34% vs 37%, P ¼ .6) or 30-day mortality (0.8% vs 1%,diovascular Surgery c Volume 148, Number 5 2061
TABLE 1. Baseline characteristics of entire cohort (all BAV patients) and 3 patient subgroups
Variable
Entire cohort
(n ¼ 456)
Subgroups
AVR AD<45 mm
(n ¼ 245)
AVR/AN AD 45-49 mm
(n ¼ 70)
AVR/AN AD  50 mm
(n ¼ 103) P value
Age (y) 57.8  13.3 61.1  13.2 53.8  12.8 54.0  11.5 <.001
Weight (kg) 84.6  18.2 82.7  17.9 86.1  18.8 88.7  18.7 .016
Body surface area (m2) 2.0  0.3 2.0  0.3 2.0  0.2 2.1  0.3 .003
Aortic stenosis only 120 (26) 79 (32) 13 (19) 19 (18) .007
Aortic insufficiency 2 only 121 (27) 42 (17) 27 (39) 36 (35) <.001
Aortic stenosis and insufficiency 202 (44) 124 (40) 28 (40) 39 (38) .05
No aortic stenosis or insufficiency 12 (3) 0 (0) 2 (3) 9 (9) <.001
Ejection fraction (%) .48
Median 60.0 60.0 60.0 60.0
Q1, Q3 53.0, 65.0 50.0, 65.0 55.0, 65.0 55.0, 63.0
Cross-section aortic ratio* (cm2/m) <.001
Median 8.0 6.2 9.8 12.4
Q1, Q3 6.0, 10.6 5.0, 7.4 9.2, 10.4 11.4, 13.7
Female gender 110 (24) 71 (29) 11 (16) 19 (18) .022
Current smoker 20 (4) 12 (5) 2 (3) 3 (3) .59
Diabetes 47 (10) 35 (14) 6 (9) 5 (5) .029
Dyslipidemia 242 (53) 149 (61) 31 (44) 43 (42) .001
Renal failure 8 (2) 7 (3) 0 (0) 1 (1) .22
Hypertension 238 (52) 136 (56) 40 (57) 49 (48) .33
Chronic lung disease 38 (8) 24 (10) 5 (7) 7 (7) .59
Peripheral vascular disease 9 (2) 7 (3) 1 (1) 1 (1) .49
Cerebrovascular disease 31 (7) 20 (8) 5 (7) 4 (4) .36
Previous stroke 15 (3) 8 (3) 3 (4) 2 (2) .66
Previous CABG 13 (3) 10 (4) 1 (1) 1 (1) .21
Previous valve procedure 30 (7) 12 (5) 6 (9) 8 (8) .40
Previous other cardiac surgery 12 (3) 9 (4) 0 (0) 3 (3) .27
Previous PCI 23 (5) 17 (7) 1 (1) 3 (3) .09
Previous MI 19 (4) 14 (6) 1 (1) 2 (2) .13
CHF 94 (21) 65 (27) 12 (17) 9 (9) <.001
NYHA class III-IV 109 (24) 76 (31) 13 (19) 12 (12) <.001
AF history 61 (13) 35 (14) 2 (3) 18 (17) .015
Angina 57 (13) 38 (16) 8 (11) 7 (7) .08
Data presented as n (%), unless otherwise noted. BAV, Bicuspid aortic valve; AVR, aortic valve replacement; AD, aortic diameter; AN, aneurysm; AVR/AN, AVR with ascending
aortic replacement; Q, quartile; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; MI, myocardial infarction; CHF, congestive heart failure;
NYHA, New York Heart Association; AF, atrial fibrillation. *Calculated as the aortic cross-sectional area (in square centimeters) divided by the patient’s height (in meters).
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DP ¼ .9). The midterm survival-adjusted HR (AVR refer-
ence) was 0.83 (95% CI, 0.34-2.03; P ¼ .7). Of 44
reoperations, the 30-day mortality was 0% for AVR only
(n ¼ 23) and for AVR/AN (n ¼ 21). We were unable to
ascertain the cause of death for the late deaths, because
all occurred outside our institution. Two AVR patients
required reoperation: one for structural valve degeneration
after 7 years and one for endocarditis after 2 years. No reop-
erations occurred in the AVR/AN group.
In the entire cohort (n ¼ 456), 5 patients had an AD of
45 mm (45 mm, n ¼ 1; 46 mm, n ¼ 3; and 47 mm,
n ¼ 1) but did not undergo aortic replacement surgery.
The treatment of these 5 patients was not in compliance
with the 2006 guidelines; thus, for the total AVR cohort
of 250, this yielded a 98% compliance rate. Of these 5, 12062 The Journal of Thoracic and Cardiovascular Surpatient underwent AVR before the 2006 ACC/AHA guide-
lines were published, and 2 underwent aortoplasty. In addi-
tion, 33 patients underwent AVR/AN with an AD<45 mm.
All 103 patients with an AD of 50 mm underwent AVR
(100% compliance with the 2006 ACC/AHA guidelines).
The data from these 38 (5 plus 33) patients were not
included in Tables 1 and 2; our tabulated analysis of the
subgroups: (1) AVR with an AD<45 mm (n ¼ 245); (2)
AVR/AN with an AD of 45 to 49 mm (n ¼ 70); and (3)
AVR/AN with an AD of 50 mm (n ¼ 103).
Within the AVR AD<45-mm group, 235 (96%) had
received a bioprosthetic valve (Table 2). In the AVR/AN
AD 45- to 49-mm and AVR/AN AD 50-mm groups (70
plus 103, n ¼ 173), 139 patients (80%) underwent aortic
root replacement with a valve conduit (Bentall procedure;gery c November 2014
FIGURE 1. Assessment of the overall balance in baseline covariates in the
3 propensity score (PS)-matched analyses. Similarity in kernel-smoothed
PS histograms depicted indicated adequate balance between the
groups compared. AVR, Aortic valve replacement; AD, aortic diameter;
AN, aneurysm.
Rinewalt et al Acquired Cardiovascular Disease
A
C
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valves sewn into a Dacron graft. Of the remaining AVR/AN
patients, 20 (11.6%) underwent AVR with a separate aortic
graft and 13 (7.5%) underwent valve-sparing aortic root
replacement (Table 2).
Other preoperative, intraoperative, and postoperative
characteristics of the entire cohort and the 3 subgroups
are summarized in Tables 1 and 2. Results from the 3 PS-
matched pairwise comparisons (AVR AD <45 mm,
n ¼ 245; AVR/AN AD 45 to 49 mm, n ¼ 70; and AVR/
AN AD  50 mm, n¼103) are listed in Table 3.Analysis 1: AVRWith AD<45 mm Compared With
AVR/AN With AD 45 to 49 mm
In the original groups (245 AVR and 70 AVR/ANAD 45-
to 49-mm patients), no significant differences were found in
overall survival (adjusted HR, 0.24; 95% CI, 0.05-1.12;
P¼ .07, AVR reference group). After PS matching, 47 pairs
were created, and the 30-day mortality was 0% in both
groups (Table 3). As displayed in Figure 1, the kernel-
smoothed histograms of the PS values were virtually iden-
tical, indicating an excellent overall baseline covariateThe Journal of Thoracic and Carbalance. The aortic crossclamp time, cardiopulmonary
bypass time, and the use of circulatory arrest were greater
in the AVR/AN group (P<.001; Table 3). No differences
were found in morbidity. The medium-term overall survival
was not significantly different (adjusted HR, 1.25; 95% CI,
0.16-9.87; P ¼ .83), with a 5-year survival of 94.0% in the
AVR cohort and 95.7% in the AVR/AN group (Figure 2).
Analysis 2: AVRWith AD<45 mm Compared With
AVR/AN With AD  50 mm
We found no significant differences in the medium-term
overall survival between the 245 AVR patients (reference
group) and 103 AVR/AN AD  50-mm patients (adjusted
HR, 1.0; 95% CI, 0.36-2.8; P ¼ 1.0). After PS matching,
62 pairs were created. Adequate baseline covariate balance
was achieved, reflected by the PS distribution similarity
shown in Figure 1. No significant difference was found in
30-day mortality (0% in AVR vs 3.2% in AVR/AN,
P ¼ .15; Table 3). The AVR/AN patients had significantly
longer perfusion and crossclamp times, a greater use of cir-
culatory arrest (P< .001), and a significantly greater risk
of prolonged ventilation (8% vs 0%, P ¼ .022) and reintu-
bation (10% vs 0%, P¼ .012; Table 3). No other significant
differences were found in morbidity or all-cause mortality
(adjusted HR, 1.59; 95% CI, 0.52-4.87; P ¼ .42), with
5-year survival at 89.9% in the AVR and 88.1% in the
AVR/AN group (Figure 2).
Analysis 3: AVR/ANWithAD 45 to 49mmCompared
With AVR/AN With AD  50 mm
In the original groups, 70 patients were in the AVR/AN
AD 45- to 49-mm and 103 were in the AVR/AN AD 
50-mm group. No significant differences in overall survival
were found (adjusted HR, 3.03; 95% CI, 0.61-15.02;
P ¼ .2; AVR/AN AD 45- to 49-mm reference group). A to-
tal of 36 PS-matched pairs were obtained. The data shown
in Figure 1 indicate adequate baseline covariate balance
between groups. No significant difference was found in
30-day mortality (0% in the AVR/AN AD 45- to 49-mm
group and 2.8% in the AVR/AN AD  50-mm group;
P ¼ .31; Table 3). The cardiopulmonary bypass duration
and crossclamp time were longer in the AVR/AN AD 
50-mm cohort (P ¼ .05), and the use of circulatory arrest
was greater (P<.001; Table 3). Reintubation was greater
in the AVR/AN AD  50-mm group (11% vs 0%,
P ¼ .040; Table 3). Medium-term survival was not signifi-
cantly different (adjusted HR, 2.35; 95% CI, 0.12-45.94;
P ¼ .57), with a 5-year survival rate at 97.2% among pa-
tients with smaller aneurysms and 90.2% among those
with larger aneurysms (Figure 2).
DISCUSSION
In the present study, our primary finding was that the
addition of aortic aneurysm replacement in patients withdiovascular Surgery c Volume 148, Number 5 2063
TABLE 2. Intraoperative, postoperative characteristics of the entire cohort (all with BAV) and 3 subgroups
Variable
Entire cohort
(n ¼ 456)
Subgroups
AVR AD<45 mm
(n ¼ 245)
AVR/AN
AD 45-49 mm (n ¼ 70)
AVR/AN AD  50 mm
(n ¼ 103) P value
Aortic valve implant size (mm) <.001
Median 25.0 23.0 25.0 27.0
Q1, Q3 23.0, 27.0 23.0, 25.0 25.0, 27.0 25.0, 27.0
Perfusion time (min) <.001
Median 108.0 82.0 135.0 170.0
Q1, Q3 79.0, 155.0 66.0, 112.0 105.0, 182.0 127.0, 208.0
Crossclamp time (min) <.001
Median 92.0 71.0 119.0 133.0
Q1, Q3 67.0, 128.0 56.0, 91.0 94.0, 138.0 109.0, 164.0
Circulatory arrest 93 (20) 0 (0) 22 (31) 65 (63) <.001
CABG 89 (20) 64 (26) 11 (16) 8 (8) <.001
Mitral valve surgery 26 (6) 20 (8) 1 (1) 2 (2) .018
Tricuspid valve surgery 9 (2) 9 (4) 0 (0) 0 (0) .039
Pulmonic valve surgery 2 (0) 0 (0) 1 (1) 1 (1) .22
Other cardiac surgery 247 (54) 39 (16) 70 (100) 103 (100) <.001
AF ablation surgery 44 (10) 26 (11) 2 (3) 11 (11) .12
Other noncardiac surgery 6 (1) 0 (0) 4 (6) 2 (2) .002
IABP inserted 3 (1) 2 (1) 0 (0) 1 (1) .73
Postoperative blood products use 191 (42) 98 (40) 30 (43) 44 (43) .85
Repeat sternotomy 44 (10) 22 (9) 7 (10) 10 (10) .96
Reintubation 16 (4) 6 (2) 3 (4) 6 (6) .29
Aortic valve surgery <.001
Repair or reconstruction 8 (2) 7 (3) 0 (0) 1 (1)
Replacement only 239 (52) 234 (96) 0 (0) 0 (0)
Replacement and separate insertion of
aortic conduit
25 (5) 0 (0) 11 (16) 9 (9)
Root reconstruction with valve conduit 170 (37) 4 (2) 56 (80) 83 (81)
Root reconstruction with valve sparing 13 (3) 0 (0) 3 (4) 10 (10)
Aortic valve implant type <.001
Bioprosthesis 418 (92) 235 (96) 64 (91) 85 (83)
Homograft 5 (1) 3 (1) 1 (1) 0 (0)
Mechanical 11 (2) 0 (0) 2 (3) 7 (7)
None 22 (5) 7 (3) 3 (4) 11 (11)
Total ICU stay (h) .65
Median 28.3 28.1 30.2 26.7
Q1, Q3 23.2, 48.3 23.5, 46.7 22.8, 50.6 22.7, 48.4
Length of hospital stay (d) .83
Median 5.0 5.0 5.0 5.0
Q1, Q3 4.0, 6.0 4.0, 6.0 4.0, 6.0 4.0, 6.0
Readmitted to ICU 21 (5) 15 (6) 2 (3) 2 (2) .18
Complications 162 (36) 85 (35) 28 (40) 36 (35) .71
Reoperation for bleeding 30 (6.6) 14 (5.7) 10 (14.3) 4 (3.9) .017
Perioperative MI 1 (0.2) 0 (0) 1 (1.4) 0 (0) .08
Sternum deep infection 0 (0) 0 (0) 0 (0) 0 (0) NA
Postoperative stroke>24 h 3 (0.7) 0 (0) 0 (0) 1 (1) .22
TIA 2 (0.4) 1 (0.4) 1 (1) 0 (0) .40
Prolonged ventilation>24 h 28 (6) 11 (4) 6 (8.6) 6 (5.8) .41
Pulmonary embolism 2 (0.4) 1 (0.4) 0 (0) 1 (1) .64
Pneumonia 11 (2.4) 9 (3.7) 0 (0) 2 (1.9) .21
Renal failure 16 (3.5) 10 (4) 2 (2.9) 4 (3.9) .89
Permanent pacemaker 17 (4) 11 (4) 2 (2.9) 4 (3.9) .83
(Continued)
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TABLE 2. Continued
Variable
Entire cohort
(n ¼ 456)
Subgroups
AVR AD<45 mm
(n ¼ 245)
AVR/AN
AD 45-49 mm (n ¼ 70)
AVR/AN AD  50 mm
(n ¼ 103) P value
Cardiac arrest 7 (1.5) 4 (1.6) 1 (1) 1 (1) .89
Postoperative AF 93 (20) 50 (20) 17 (24) 19 (18) .64
Readmission within 30 d 55 (12) 27 (11) 8 (12) 16 (16) .48
Discharge mortality 5 (1.1) 2 (0.8) 1 (1.4) 2 (1.9) .67
30-d Mortality 4 (0.9) 2 (0.8) 0 (0) 2 (1.9) .41
Operative mortality 5 (1.1) 2 (0.8) 1 (1.4) 2 (1.9) .67
All-cause medium-term mortality 37 (8.1) 24 (9.8) 2 (2.9) 9 (8.7) .18
Data presented as n (%), unless otherwise noted. AVR, Aortic valve replacement; AD, aortic diameter; AN, aneurysm; AVR/AN, AVR with ascending aortic replacement; Q, quar-
tile; CABG, coronary artery bypass grafting; AF, atrial fibrillation; IABP, intra-aortic balloon pump; ICU, intensive care unit;MI, myocardial infarction; TIA, transient ischemic
attack; NA, not applicable.
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DBAVand aortic dilatation of 45 to 49 mm can be performed
safely without increasing the short- or medium-term
morbidity or mortality. Aortic replacement to eliminate
the threat of future dissection in patients with BAV can be
accomplished with only an increase in pulmonary compli-
cations in those with larger ANs (50 mm). The decision
to systematically commit to prophylactic aortic replace-
ment in patients with BAV is complex. The 2006 ACC/
AHA guidelines were based on expert opinion and multipleTABLE 3. Propensity score-matched analyses: pairwise comparisons of p
interest
Variable
PS-matched analysis 1
AVR
AD<45 mm
(n ¼ 47)
AVR/AN
AD 45-49 mm
(n ¼ 47)
P
value
A
AD<
(n
Perfusion time (min) <.001
Median 79 133
Q1, Q3 65, 124 105, 171 69
Crossclamp time (min) <.001
Median 70 116
Q1, Q3 56, 97 94, 135 57
Reintubation 0 (0) 2 (4.3) .15 0
Circulatory arrest 0 (0) 14 (30) <.001 0
Complications 16 (34) 21 (45) .29 18
Reoperation for bleeding 3 (6.4) 7 (15) .18 3
Perioperative MI 0 (0) 1 (2.1) .31 0
Postoperative stroke>24 h 0 (0) 0 (0) NA 0
TIA 1 (2.1) 1 (2.1) 1.00 0
Ventilation>24 h 2 (4.2) 5 (11) .24 0
Pulmonary embolism 1 (2.1) 0 (0) .31 0
Pneumonia 1 (2.1) 0 (0) .31 2
Renal failure 3 (6.4) 2 (4.3) .65 1
Permanent pacemaker 1 (2.1) 2 (4.3) .56 1
Cardiac arrest 0 (0) 1 (2.1) .31 0
Readmission within 30 d 6 (13) 6 (13) .97 11
Discharge mortality 0 (0) 1 (2.1) .31 0
30-d Mortality 0 (0) 0 (0) NA 0
All-cause midterm mortality 2 (4.3) 2 (4.3) 1.00 5
Data presented as n (%), unless otherwise noted. PS, Propensity score; AVR, aortic valve re
replacement; Q, quartile; MI, myocardial infarction; TIA, transient ischemic attack; NA, n
The Journal of Thoracic and Carreports of adverse outcomes in patients with BAV and un-
treated aortic dilatation>45 mm. Most recently, the 2013
Society of Thoracic Surgeons clinical practice guidelines
have also reflected these concerns.10 They have concurred
with the 2006 ACC/AHA guidelines by recommending
that patients with genetically associated aortic disease (eg,
BAV) should undergo aortic replacement when the AD
has exceeded 50 mm and have taken the aggressive stance
that aortic repair is indicated for all cardiac surgery patientserioperative and postoperative outcomes among the 3 subgroups of
PS-matched analysis 2 PS-matched analysis 3
VR
45 mm
¼ 62)
AVR/AN
AD  50 mm
(n ¼ 62)
P
value
AVR/AN
AD 45-49 mm
(n ¼ 36)
AVR/AN
AD  50 mm
(n ¼ 36)
P
value
<.001 .05
84 146 135 171
, 120 118, 191 111, 174 134, 198
<.001 .05
72 126 119 130
, 97 98, 148 99, 137 114, 152
(0) 6 (9.7) .012 0 (0) 4 (11) .040
(0) 40 (65) <.001 12 (33) 27 (75) <.001
(29) 25 (40) .19 13 (36) 15 (42) .63
(4.8) 4 (6.5) .70 3 (8.3) 3 (8.3) 1.00
(0) 0 (0) NA 0 (0) 0 (0) NA
(0) 1 (2) .32 0 (0) 0 (0) NA
(0) 0 (0) NA 0 (0) 0 (0) NA
(0) 5 (8) .022 3 (8.3) 2 (5.6) .64
(0) 1 (1.6) .32 0 (0) 0 (0) NA
(3.2) 2 (3.2) 1.00 0 (0) 1 (2.8) .31
(1.6) 4 (6.5) .17 0 (0) 2 (5.6) .15
(1.6) 2 (3.2) .56 0 (0) 2 (5.6) .15
(0) 1 (1.6) .32 0 (0) 1 (2.8) .31
(18) 8 (13) .48 4 (11) 5 (14) .69
(0) 2 (3.2) .15 0 (0) 1 (2.8) .31
(0) 2 (3.2) .15 0 (0) 1 (2.8) .31
(8.1) 7 (11.3) .54 1 (2.8) 3 (8.3) .30
placement; AD, aortic diameter; AN, aneurysm; AVR/AN, AVR with ascending aortic
ot applicable.
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FIGURE 2. Propensity score (PS)-matched analyses with Kaplan-Meier overall survival curve estimates for pairwise comparisons among the 3 subgroups
of interest (aortic valve replacement [AVR] aortic diameter [AD]<45mm, AVR/aneurysm [AN] AD 45-49 mm and AVR/AN AD  50 mm). Log-rank
test-based P values are reported for each 2-group comparison.
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Dwhen the AD exceeds 45 mm.10 Addressing the aorta at
AVR for those with an AD of 45 to 49 mm, however, adds
to the complexity of the operation, which was shown by
the longer crossclamp and cardiopulmonary bypass times
and, sometimes, the use of circulatory arrest. However,
this approach might avoid the complexity of a redo opera-
tion in patients who progress to aortic dilatation after
AVR alone. Among our patients, no increase was seen in
the incidence of perioperativemyocardial infarction, stroke,
hospital length of stay, 30-day hospital readmission, or 30-
day mortality in the AVR/AN group, with the exception of
respiratory factors in those with an AD of 50 mm. These
findings provide further support toward continued2066 The Journal of Thoracic and Cardiovascular Surcompliance with contemporary guidelines. Circulatory ar-
rest to facilitate hemiarch replacement was performed in
93 patients (20%); however, it was mostly performed in
those (n ¼ 65) with larger (50 mm) ANs with arch dilata-
tion, of whom 63% had circulatory arrest. This decision
was at the discretion of the surgeon on the basis of the distal
ascending and arch diameters.
Previous studies of patients with BAV have suggested a
threshold of 45 mm for consideration of concomitant aortic
replacement at AVR. Svensson and colleageus11 reported
findings from a less contemporary series of 1810 patients
(1993-2003), with 20% undergoing AVR/AN compared
with 45% in our series. Most of their AVR cohort (95%)gery c November 2014
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in 30-day mortality (1.2% vs 1.1% in the AVR and AVR/
AN group, respectively) and similar freedom-from-late
aortic events in each group (99% for AVR vs 97% in
AVR/AN at 10 years). The investigators concluded that
aortic dilatation>45 mm should be considered a criterion
for aortic replacement, because no additional short-term
risk was found, with favorable long-term survival.11 Our re-
sults were similar to those from the Cleveland Clinic study
but more contemporary. Also, our series included 91% of
patients with BAV who had undergone preoperative CT or
MRI, unique in published studies. These 2 factors likely ac-
count for the 45% AN resection in our group compared
with 20% in the Cleveland series. Furthermore, we
analyzed not just PS-matched AVR and AVR/AN groups
but also the 3 subgroups.
Fedak and colleagues12 and Borger and colleagues13 have
reported that patients with BAV and aortic root measure-
ments of 45 to 50 mm undergoing isolated AVR have signif-
icantly greater risk of aortic ANs, dissections, and sudden
death during follow-up. Russo and colleagues14 examined
a series of 100 patients undergoing AVR (50 with BAVand
50 with a tricuspid aortic valve) and found significantly
greater rates of acute aortic dissection and sudden death in
the BAV group during nearly 20 years of follow-up. They
recommended aggressive aortic replacement in patients
with BAV and AD> 40 mm during concomitant AV sur-
gery.14 A recent review by Hardikar and Marwick15 com-
bined the results of 32 studies and included 9441 patients
with BAV, with 90% complete follow-up at an average of
7.7 years. They divided them into 3 groups: (1) those who
did not undergo any operative intervention, (2) those who
underwent AVR only, and (3) those who underwent any
intervention on the aorta.15 They reported an annual mortal-
ity in the unoperated, AVR, and aortic surgery groups of
0.56%  0.22%, 2.4%  0.4%, 0.16%  0.08%, respec-
tively.15 Additionally, they reported corresponding annual
rates of acute aortic events, defined as the need for reinter-
vention on the proximal aorta, aortic dissection or rupture,
or sudden death not attributable to another cause, by group,
of 0.29%  0.03%, 0.68%  0.13%, and 0.16% 
0.08%.15 Our study was unique in that we performed a
detailed analysis of the data from a contemporary series of
patients to examine the effect of compliancewith the current
ACC/AHA guidelines. Despite excellent review reports16
and expert commentary, a detailed analysis of the short-
and medium-term outcomes when complying with the pre-
sent guidelines has not been reported.
In contrast to these cited studies, controversy exists
because others have suggested that an aortic root dimension
of 45 mm in BAV might not be an appropriate criterion for
prophylactic replacement. In a series of 252 patients with
BAV who underwent surgery and were subsequently fol-
lowed up for 9 years, Goland and colleagues17 identified aThe Journal of Thoracic and Carmoderately dilated aorta (45-49 mm) in only 15.5% of
patients, much lower than the 45% in our series. Aortic
dilatation was not independently associated with increased
mortality risk, and no significant differences in cardiac
death were found between the AVR patients without aortic
dilatation and thosewith AD of 45 to 49 mm. Similarly, Gir-
dauskas and colleagues18 recently reported on their 15-year
follow-up in a series of patients with aortic stenosis and
associated dilatation of 40 to 50 mm, of whom 153 (47%)
had BAV. Only 3% of those with BAV and a dilated aorta
in their cohort underwent repeat surgery during the duration
of follow-up with no cases of aortic dissection.18 In addi-
tion, Michelena and colleagues19,20 recently reported a
20-year follow-up of 416 patients in Olmsted County Min-
nesota and reported excellent survival, with no aortic dis-
sections, in patients with BAV and close clinical follow-up
and no significant aortic stenosis or insufficiency. However,
in our surgical series, the vast majority had aortic stenosis or
aortic regurgitation, or both (Table 1).
A critique by Guntheroth21 on the present ACC/AHA
guidelines suggested that in patients with BAV undergoing
AVR, the risk of dissection might not outweigh the addi-
tional surgical mortality and morbidity associated with pro-
phylactic aortic replacement. Given the low (3%) rate of
dissection attributed to BAV in the International Registry
of Acute Aortic Dissection,22 the short- and long-term mor-
tality (4% and 10%, respectively) of aortic replacement
was considered unacceptable. In a rebuttal, Bonow23
pointed out that previous studies had documented a 5 to
10 times greater risk of dissection in patients with BAV
compared with that of the general population and that
BAV was found in 13.6% of all acute dissections. These
differing results from single-center studies have ranged
from a benign long-term course (1 reoperation for aortic
AN in a subgroup of 252 patients with BAV)17 to a markedly
unfavorable postoperative course (8 late aortic events and 7
sudden deaths in the subgroup of 50 patients with BAV).14
Ultimately, for prophylactic aortic replacement to be
routinely performed in patients with an AD of 45 to 49
mm, the morbidity and mortality rate must be especially
low, such as it was in our study (0.9% mortality). Hughes
and colleagues24 recently reported greater mortality in hos-
pitals performing<30 to 40 aortic procedures annually. A
recent study using the Nationwide Inpatient Sample from
the Healthcare Cost and Utilization Project revealed a
substantial increase in the proportion of concomitant aortic
procedures in patients with BAV undergoing AVR from
1998-1999 compared to 2008-2009 (12.8% to 28.5%).25
Their data revealed no difference in mortality between the
AVR and AVR/AN patients (1.5% vs 1.8%; odds ratio,
1.02; 95% CI, 0.67-1.57).25
The precise etiology for aortic dilatation in patients with
BAV disease remains unclear. The widespread belief that
BAV disease is a congenital disorder of vascular connectivediovascular Surgery c Volume 148, Number 5 2067
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treatment recommendations of the proximal aorta in this
patient population14,17 and is a philosophy that we have
adopted. Although aortic dissection and rupture remain
the most serious concerns with failure to proceed with
complete resection of tissue at risk of molecular
degeneration, it is likely that any sudden event would be
preceded by progressive dilatation that would be
diagnosed during follow-up or when symptoms arise. The
complexity of a redo operation to replace the aortic root
in a patient who has undergone an AVR is considerable,
and, given the low morbidity and mortality of aggressive
resection at AVR reported in our study, is likely an unnec-
essary risk.
Current guidelines are limited in that they fail to address a
specific operative approach for individual patients with
BAVaortopathy. It is now well recognized that BAVaortop-
athy is heterogeneous,26 and different patterns of aortic
dilatation might relate to the location of cusp fusion.
Accordingly, guidelines based on grouped data might be
too conservative or too aggressive with respect to aortic
replacement in this patient population. The use of 4-
dimensional MRI to map strain in the aorta might be
capable of guiding surgeons toward individualized resec-
tion strategies; however, additional validation is needed
before guidelines can be established. In the absence of
such guidance, most patients in our series underwent a Ben-
tall procedure with a bioprosthetic valve conduit to
completely remove any tissue at risk of degeneration sec-
ondary to the underlying mechanisms suspected in BAV
disease. Our outcomes using the Bentall procedure in this
cohort of patients with BAV was 0.6% 30-day mortality
and 94.2% 3-year overall survival. Some might criticize
our approach as too aggressive, because other published
studies have reported a mortality range of 3.6% to as great
as 11%.27-30 However, we think complete resection of the
pathologic features is ideal and, as our results have
demonstrated, will not increase mortality. A few of the
AVR/AN cohort (11.6%) underwent valve replacement
with a separate aortic graft at the discretion of the
surgeon, leaving the native supracoronary aortic tissue. A
few received valve-sparing aortic root replacement. We
found no differences in short- or medium-term mortality
between these techniques.
Most of the complications reported in our study were res-
piratory in nature, specifically reintubation in patients with
ANs>50 mm. These patients were also significantly more
likely to undergo circulatory arrest, which likely contributed
to their respiratory morbidity. Although our series of pa-
tients was not designed to investigate this, it is likely that
the postoperative treatment of these complex patients should
take into account this additional potential complication.
Because BAV is a relatively common congenital cardiac
anomaly, future studies are needed to address the2068 The Journal of Thoracic and Cardiovascular Surmechanisms of aortic aneurysm formation in this patient
population and potential prophylactic interventions to pre-
vent catastrophic events. Recent reviews have even sug-
gested the existence of multiple phenotypes of BAV
disease, leading to predominant stenosis or regurgitation,
with the latter more likely to result in a persistent aortop-
athy more likely to result in aortic dissection.31 Retrospec-
tive analysis of existing imaging data with
echocardiography, CT, and MRI have led Fazel and col-
leagues32 to propose clustering patients with BAV into
groups according to the anatomic patterns of aortic dilata-
tion. They hypothesized that this novel categorization
would lead to individualized recommendations for the
extent of surgical intervention required.32 In addition,
novel imaging methods such as multidetector CT33 and
4-dimensional MRI34 might improve risk stratification
for those patients with BAV and aortopathy and predict
the likelihood of progression and complications that might
warrant earlier surgical intervention.
Study Limitations
Surgical decision making hinges on the ratio of risk to
benefit. The present study focused only on the near-term
risk of adding aneurysm surgery to patients with BAV.
The long-term benefit of this approach must be derived
from the published data because our compliance with the
guidelines was so high. However, the exact risk of aortic
complications in patients with BAV has been somewhat
controversial. With our average patient age of 58 years, in
our experience, untreated patients would face decades of
risk from aortopathy complications.
Aortic dimensions were obtained by CT or magnetic
resonance angiography in 91.4% of the entire cohort of
456 patients with BAV. The remainder had aortic dimen-
sions obtained from echocardiography alone, which might
have some inherent limitations for accurate aortic diameter
measurements. However, previous studies of patients with
BAV have primarily used aortic measurements obtained by
echocardiography.11 The average follow-up of 4.7  2.1
years in our study was shorter than that in other similar
studies. Therefore, continued follow-up for adverse events
is warranted in our patient population; however, our
primary focus was on perioperative morbidity and
mortality, which was comparable in the 2 groups. Late
outcome data on death was determined from the Social
Security Death Index, while other outcomes such as the
incidence of aortic dissection might have been less
complete. Although some concerns exist that PS matching
will decrease the overall sample size, it must be
emphasized that the AVR-only cohort was substantially
older, with significant differences in multiple comorbi-
dities, including, but not limited to, diabetes, heart failure,
previous myocardial infarction, advanced New York Heart
Association class (III and IV), and previous cardiacgery c November 2014
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matching, therefore, was an effective method to
eliminate such imbalances, and hence reduce the potential
confounding, at the expense of sample size.
CONCLUSIONS
We have shown that in patients with BAV, we had 98%
compliance with the 2006 ACC/AHA recommendations
for prophylactic aortic replacement in those with an AD
of 45 mm at surgery. We found similar short- and
medium-term mortality outcomes compared with AVR
alone. This approach could prevent future aortic aneurysm
complications and is, therefore, justified in centers with
similar perioperative outcomes.
This work would not have been possible without the assistance
of the support staff in the Division of Cardiac Surgery at North-
western University and the Bluhm Cardiovascular Institute,
including Jane Kruse, Colleen Clennon, and Linda Huerta.
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